Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | TYMS | P04818 | 1/20 | 0.60 |
| ▸ | BCHE | P06276 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22943603 | 1.00 | TK1 (0.69) | TK1POLBTYMSBCHE | |
| SCHEMBL17236294 | 1.00 | TK1 (0.69) | TK1POLBTYMSBCHE | |
| SCHEMBL4198253 | 1.00 | TK1 (0.69) | TK1POLBTYMSBCHE | |
| SCHEMBL522285 | 1.00 | TK1 (0.69) | TK1POLBTYMSBCHE | |
| SCHEMBL17232081 | 1.00 | TK1 (0.69) | TK1POLBTYMSBCHE | |
| SCHEMBL12918450 | 1.00 | TK1 (0.69) | TK1POLBTYMSBCHE | |
| SCHEMBL8470853 | 0.91 | TK1 (0.64) | TK1POLBTYMSBCHE | |
| SCHEMBL7571044 | 0.91 | TK1 (0.66) | TK1POLBTYMSBCHE | |
| SCHEMBL4804983 | 0.91 | POLB (0.68) | TK1POLBTYMSBCHE | |
| SCHEMBL6379335 | 0.91 | POLB (0.68) | TK1POLBTYMSBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 737 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118043078-A | SIRP-alpha antibodies and conjugates | 塔拉克治疗公司 | 2024-05-14 | — | — | CN | claimed |
| CN-117836413-A | Connexin-4 antibodies and conjugates | 塔拉克治疗公司 | 2024-04-05 | — | — | CN | claimed |
| EP-4110365-A2 | FIDGETIN-LIKE 2 AS A TARGET TO ENHANCE WOUND HEALING | Microcures, Inc. (US) | 2023-01-04 | — | — | EP | claimed |
| CN-115427458-A | Transglutaminase mediated conjugation | 塔拉克治疗公司 | 2022-12-02 | — | — | CN | claimed |
| WO-2019195494-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIS OF PHOSPHORYLATED MOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-10 | — | — | WO | claimed |
| CN-105596356-A | Compositions and methods for combination antiviral therapy | GILEAD SCIENCES INC | 2016-05-25 | — | — | CN | claimed |
| US-9249173-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, LLC (US) | 2016-02-02 | — | — | US | claimed |
| EP-0767842-B1 | METHODS OF SCREENING FOR NUCLEOSIDE ANALOGS THAT ARE INCORPORATED BY HIV REVERSE TRANSCRIPTASE AND CAUSE INCORRECT BASE PAIRING | UNIV WASHINGTON (US) | 2000-09-27 | — | — | EP | claimed |
| EP-1004675-A2 | Methods of screening for nucleoside analogs that are incorporated by HIV reverse transcriptase and cause incorrect base pairing | DARWIN MOLECULAR CORPORATION (US) | 2000-05-31 | — | — | EP | claimed |
| EP-0767842-A1 | METHODS OF SCREENING FOR NUCLEOSIDE ANALOGS THAT ARE INCORPORATED BY HIV REVERSE TRANSCRIPTASE AND CAUSE INCORRECT BASE PAIRING | DARWIN MOLECULAR CORPORATION (US) | 1997-04-16 | — | — | EP | claimed |
| WO-1996000797-A1 | METHODS OF SCREENING FOR NUCLEOSIDE ANALOGS THAT ARE INCORPORATED BY HIV REVERSE TRANSCRIPTASE AND CAUSE INCORRECT BASE PAIRING | DARWIN MOLECULAR CORP (US) | 1996-01-11 | — | — | WO | claimed |
| US-12584168-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-24 | — | — | US | disclosed |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | OPENTRONS LABWORKS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12527846-B2 | Immunodominant proteins and fragments in multiple sclerosis | Universität Zürich (CH) | 2026-01-20 | — | — | US | disclosed |
| US-20250345413-A1 | SARS-COV-2 SUBUNIT VACCINE | Viravaxx AG (AT) | 2025-11-13 | — | — | US | disclosed |
| US-4444776-A | ANTITUMOR, ANTIVIRAL | AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (A N V A R) (FR) | 1984-04-24 | — | — | US | disclosed |
| EP-0099133-A2 | Anti-cancer drugs comprising platinum complexes | YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD. (IL) | 1984-01-25 | — | — | EP | disclosed |
| US-4377514-A | HOMOGENIZING, ACIDIFYING, DENATURING, AND CENTRIFUGING INTESTINAL LYMPH GLANDS; HORMONES | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1983-03-22 | — | — | US | disclosed |
| US-4266060-A | ANTITUMOR ANTIVIRAL AGENTS FOR TREATMENT OF CANCER | AGENCE NATIONALE DE VAL ORISATION DE LA RECHERCHE (ANVAR) (FR) | 1981-05-05 | — | — | US | disclosed |
| US-4064007-A | ANTITUMOR AGENTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1977-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584168-B2 | Sample preparation method | POLN, POLRMT, POLM | TK1 472/4885POLB 4/4885TYMS 273/4885 |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | POLRMT, POLL, SARS1 | TK1 1713/4885POLB 12/4885TYMS 179/4885 |
| US-12527846-B2 | Immunodominant proteins and fragments in multiple sclerosis | MAG, GMFG, FUCA1 | TK1 3147/4885POLB 4725/4885TYMS 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.